09:40 AM EDT, 09/15/2025 (MT Newswires) -- Krystal Biotech ( KRYS ) said Monday the US Food and Drug Administration has approved an updated label for Vyjuvek, to include treatment for dystrophic epidermolysis bullosa as a wound dressing from birth.

The updated label expands the eligible patient population and allows patients and caregivers to apply Vyjuvek at home on their own when changing wound dressings, the company said.

Wound dressings can also be removed as part of the next dressing change rather than after 24 hours, the company said.

Krystal Biotech ( KRYS ) said the label update is supported by real-world data and an open-label extension study.

Shares of the company were up 3.3% in recent Monday trading.

Price: 145.84, Change: +2.16, Percent Change: +1.50